Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients
- Conditions
- Chronic Spontaneous Uriticaria
- Interventions
- Other: PlaceboBiological: Omalizumab
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 218
- Registration Number
- NCT02329223
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
- Conditions
- Hepatocellular Carcinoma (HCC)Solid Malignancies
- Interventions
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 172
- Registration Number
- NCT02325739
- Locations
- 🇺🇸
University of California LA Santa Monica Location, Los Angeles, California, United States
🇺🇸Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸Massachusetts General Hospital Oncology Dept, Boston, Massachusetts, United States
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT02323126
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2), Houston, Texas, United States
🇨🇭Novartis Investigative Site, Chur, Switzerland
Long-term Follow-up of Fingolimod Phase II Study Patients
- Conditions
- Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
- Interventions
- Other: Assessments arm
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT02307838
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02300987
- Locations
- 🇺🇸
USC Kenneth Norris Comprehensive Cancer Center Oncology Dept, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Oncology Department., New York, New York, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 306
- Registration Number
- NCT02299505
- Locations
- 🇺🇸
Goshen Center for Cancer Care IU Health - SC, Indianapolis, Indiana, United States
🇺🇸Loma Linda University, Loma Linda, California, United States
🇺🇸Utah Cancer Specialists Dept.of Utah Cancer Spec. (3), Salt Lake City, Utah, United States
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
- Conditions
- Systemic Juvenile Idiopathic Arthritis (SJIA)
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 182
- Registration Number
- NCT02296424
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT02294786
- Locations
- 🇬🇧
Novartis Investigative Site, Romford, United Kingdom
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
- Conditions
- Arthritis, Psoriatic
- Interventions
- Biological: SecukinumabOther: Placebo
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 341
- Registration Number
- NCT02294227
- Locations
- 🇬🇧
Novartis Investigative Site, Leytonstone, London, United Kingdom
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 161
- Registration Number
- NCT02292446
- Locations
- 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand